Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better

被引：0
|
作者：
Franchini, Massimo [1 ]
机构：
[1] Azienda Osped Univ Parma, Serv Immunoematol & Trasfus, Parma, Italy
来源：
BLOOD TRANSFUSION | 2010年 / 8卷 / 04期
关键词：
PREVIOUSLY UNTREATED PATIENTS; IMMUNE TOLERANCE INDUCTION; INHIBITOR DEVELOPMENT; CHILDREN; PURITY; EPIDEMIOLOGY; PRODUCTS; EFFICACY; COMPLEX; RISK;
D O I：
10.2450/2010.0067.10
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：292 / 296
页数：5
相关论文
共 50 条
  • [31] Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review
    Iorio, A.
    Halimeh, S.
    Holzhauer, S.
    Goldenberg, N.
    Marchesini, E.
    Marcucci, M.
    Young, G.
    Bidlingmaier, C.
    Brandao, L. R.
    Ettingshausen, C. E.
    Gringeri, A.
    Kenet, G.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Santagostino, E.
    Mannucci, P. M.
    Nowak-Goettl, U.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (06) : 1256 - 1265
  • [32] Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review
    Iorio, A.
    Halimeh, S.
    Bidlingmaier, C.
    Ettingshausen, C. E.
    Gringeri, A.
    Holzhauer, S.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Santagostino, E.
    Mannucci, P. M.
    Nowak-Goettl, U.
    HAEMOPHILIA, 2010, 16 (02) : 410 - 410
  • [33] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIII ARE IMMUNOLOGICALLY DISTINCT IN IN-VITRO ASSAYS
    GILLES, JGG
    SAINTREMY, JMR
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1213 - 1213
  • [34] The binding kinetics of B-domain-deleted recombinant factor VIII and plasma-derived factor VIII to phospholipid vesicles
    Brekkan, E
    Wrangel, M
    Sandberg, H
    THROMBOSIS AND HAEMOSTASIS, 1999, : 235 - 235
  • [35] FACTOR-VIII INHIBITOR ASSAYS USING PLASMA-DERIVED FVIII VERSUS RECOMBINANT FVIII - A COMPARATIVE-STUDY
    HILLMANWISEMAN, C
    VITALE, C
    LUSHER, J
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 684 - 684
  • [36] Plasma-derived and recombinant FVIII
    Herzog, Roland W.
    BLOOD, 2009, 114 (04) : 753 - 754
  • [37] ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES
    O'Day, K.
    Runken, M. C.
    Meyer, K. L.
    Spears, J. B.
    VALUE IN HEALTH, 2017, 20 (05) : A216 - A217
  • [38] Universal AAV Amplification and DNA Sequencing of Plasma Derived and Recombinant Factor VIII and Factor IX Concentrates
    Young, Lisa
    Marshall, Jean-Claude
    Pittman, Debra
    Smith, Justin
    Uzgiris, James
    Smith, Liam
    Philipp, Isabelle
    Winburn, Ian
    MOLECULAR THERAPY, 2022, 30 (04) : 341 - 341
  • [39] Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia
    van der Bom, Johanna G.
    Gouw, Samantha C.
    van den Berg, H. Marijke
    BLOOD, 2007, 110 (03) : 1074 - 1075
  • [40] The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis
    Kohar, Kelvin
    Prayogo, Stephanie A.
    Wiyono, Lowilius
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
12345